{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:54:17Z","timestamp":1781582057979,"version":"3.54.5"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.rdc.2014.09.003","type":"journal-article","created":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T22:59:06Z","timestamp":1416437946000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Current Landscape of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis"],"prefix":"10.1016","volume":"41","author":[{"given":"Lindsay","family":"Lally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Spiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2014.09.003_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa1108735","article-title":"Genetically distinct subsets within ANCA-associated vasculitis","volume":"367","author":"Lyons","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/art.1780330806","article-title":"The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)","volume":"33","author":"Masi","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener\u2019s granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2014.09.003_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11926-013-0383-6","article-title":"Classification of ANCA-associated vasculitis","volume":"15","author":"Khan","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2014.09.003_bib10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10157-013-0854-0","article-title":"ACR\/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS)","volume":"17","author":"Craven","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.rdc.2014.09.003_bib11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.rdc.2014.09.003_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cei.12301","article-title":"Neutrophils from vasculitis patients exhibit an increased propensity for activation by anti-neutrophil cytoplasmic antibodies","volume":"176","author":"Ohlsson","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.rdc.2014.09.003_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjmed.2006.08.016","article-title":"ANCA are detectable in nearly all patients with active severe Wegener\u2019s granulomatosis","volume":"120","author":"Finkielman","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","article-title":"Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients","volume":"42","author":"Guillevin","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrrheum.2014.78","article-title":"Current and emerging techniques for ANCA detection in vasculitis","volume":"10","author":"Csernok","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2014.09.003_bib16","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.3949\/ccjm.79.s3.02","article-title":"Controversies in ANCA testing","volume":"79","author":"Specks","year":"2012","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib17","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.20479","article-title":"Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastatse as a diagnostic marker for cocaine-induced midline destructive lesions but not auto-immune vasculitis","volume":"50","author":"Weisner","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1084\/jem.181.2.585","article-title":"A\u00a0novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells","volume":"181","author":"Kain","year":"1995","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2011090920","article-title":"High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"23","author":"Kain","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2014.09.003_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1681\/ASN.2011030273","article-title":"Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis","volume":"23","author":"Roth","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2014.09.003_bib21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1681\/ASN.V7123","article-title":"Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis","volume":"7","author":"Hogan","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2014.09.003_bib22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib23","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1002\/art.34562","article-title":"Classification of antineutrophil cytoplasmic autoantibody vasculitides. The role of ANCA specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis","volume":"64","author":"Lionaki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/ki.1995.23","article-title":"Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease","volume":"47","author":"Franssen","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2014.09.003_bib25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","article-title":"Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis","volume":"72","author":"Mahr","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-147-9-200711060-00005","article-title":"Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis","volume":"147","author":"Finkielman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2005.09.022","article-title":"Serial ANCA determinations for monitoring disease activity in patients with ANCA-Associated vasculitis: systematic review","volume":"47","author":"Birck","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/ker280","article-title":"Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis","volume":"51","author":"Tomasson","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.rdc.2014.09.003_bib29","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O","article-title":"Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study","volume":"43","author":"Boomsma","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00000478-199006000-00006","article-title":"Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients","volume":"14","author":"Devaney","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.rdc.2014.09.003_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0046-8177(91)90030-S","article-title":"Diagnostic usefulness of nasal biopsy in Wegener's granulomatosis","volume":"22","author":"Del Buono","year":"1991","journal-title":"Hum Pathol"},{"key":"10.1016\/j.rdc.2014.09.003_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2500\/ajra.2012.26.3825","article-title":"Diagnostic value of biopsies in identifying cytoplasmic antineutrophil cytoplasmic antibody-negative localized Wegener's granulomatosis presenting primarily with sinonasal disease","volume":"26","author":"Borner","year":"2012","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.rdc.2014.09.003_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1523-1755.2002.00089.x","article-title":"Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups","volume":"61","author":"Hauer","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2014.09.003_bib35","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2010050477","article-title":"Histopathologic classification of ANCA-associated glomerulonephritis","volume":"21","author":"Berden","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2014.09.003_bib36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.ajkd.2013.08.025","article-title":"Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis","volume":"63","author":"Ford","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib37","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1183\/09031936.97.10122738","article-title":"Efficacy of transbronchial biopsy in pulmonary vaculitides","volume":"10","author":"Schnabel","year":"1997","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rdc.2014.09.003_bib38","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib39","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/art.21142","article-title":"Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"De Groot","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib40","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener\u2019s Granulomatosis","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Research Group","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib41","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/art.11075","article-title":"Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial","volume":"48","author":"Stone","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib42","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1002\/art.21117","article-title":"Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET)","volume":"52","author":"Seo","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11926-013-0363-x","article-title":"Biomarkers in ANCA-associated vasculitis","volume":"15","author":"Lally","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2014.09.003_bib44","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.30296","article-title":"Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides","volume":"63","author":"Le Guenno","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib45","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib46","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib47","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ki.1991.272","article-title":"Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies","volume":"40","author":"Pusey","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.rdc.2014.09.003_bib48","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2014.09.003_bib49","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","article-title":"Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis","volume":"42","author":"Klemmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1745-6215-14-73","article-title":"Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial","volume":"14","author":"Walsh","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.rdc.2014.09.003_bib51","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1002\/art.34547","article-title":"Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis","volume":"34","author":"Faurschou","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A\u00a0randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib53","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib54","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","article-title":"Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's Granulomatosis","volume":"46","author":"Metzler","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2014.09.003_bib55","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/jama.2010.1658","article-title":"Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial","volume":"304","author":"Hiemstra","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2014.09.003_bib56","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/BOR.0b013e328346c332","article-title":"Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis","volume":"23","author":"Tadema","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2014.09.003_bib57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJM199607043350103","article-title":"Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group","volume":"335","author":"Stegeman","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2014.09.003_bib59","first-page":"542","article-title":"Rituximab for the treatment of relapses in ANCA-associated vasculitis","volume":"43","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib60","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener\u2019s): a single-center ten-year experience","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib61","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2014.03.002","article-title":"Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegeners). Results of a single-center cohort study on 66 patients","volume":"50","author":"Calich","year":"2014","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.rdc.2014.09.003_bib63","unstructured":"Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01731561. Accessed August 9, 2014."},{"key":"10.1016\/j.rdc.2014.09.003_bib64","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/ard.2011.153601","article-title":"Rituximab for refractory granulomatosis with polyangiitis: comparison of efficacy in granulomatous versus vasculitic manifestation","volume":"71","author":"Holle","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib65","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of rituximab in Wegener\u2019s granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib66","first-page":"2017","article-title":"Efficacy of rituximab in limited Wegener\u2019s with refractory granulomatous manifestations","volume":"35","author":"Seo","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.09.003_bib67","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1749-4486.2009.01968.x","article-title":"B-cell depletion with rituximab for refractory head and neck Wegener\u2019s granulomatosis: a cohort study","volume":"34","author":"Martinez","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.rdc.2014.09.003_bib68","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/acr.22311","article-title":"Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis","volume":"66","author":"Lally","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rdc.2014.09.003_bib69","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","article-title":"Brief Communication: high incidence of venous thromboembolic events among patients with Wegener\u2019s granulomatosis: the Wegener\u2019s Clinical Occurrence of Thrombosis (WeCLOT) Study","volume":"142","author":"Merkel","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib70","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/art.21704","article-title":"Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"55","author":"Weidner","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib71","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2004.029033","article-title":"Accelerated atherosclerosis in patients with Wegener's granulomatosis","volume":"64","author":"de Leeuw","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib72","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/art.24386","article-title":"Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis","volume":"60","author":"Faurschou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib73","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/acr.20433","article-title":"A\u00a0model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis","volume":"63","author":"Suppiah","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2014.09.003_bib74","article-title":"Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials","author":"Robson","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib75","first-page":"100","article-title":"Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2014.09.003_bib76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.berh.2012.12.003","article-title":"ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships","volume":"27","author":"Mahr","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.rdc.2014.09.003_bib77","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard.2010.145250","article-title":"Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials","volume":"70","author":"Heijl","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib78","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.rdc.2014.09.003_bib79","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1681\/ASN.2008050497","article-title":"C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis","volume":"20","author":"Schreiber","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2014.09.003_bib80","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a receptor (CD88) blockade protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2014.09.003_bib81","unstructured":"Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01363388. Accessed August 9, 2014."},{"key":"10.1016\/j.rdc.2014.09.003_bib82","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib83","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib84","doi-asserted-by":"crossref","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","article-title":"Antineutrophil cytoplasmic antibodies in the Churg-Strauss syndrome","volume":"143","author":"Sabl\u00e9-Fourtassou","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2014.09.003_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/BOR.0000000000000015","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management","volume":"26","author":"Mahr","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rdc.2014.09.003_bib86","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/brain\/122.3.427","article-title":"Clinicopathological features of Churg-Strauss syndrome-associated neuropathy","volume":"122","author":"Hattori","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.rdc.2014.09.003_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognositic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2014.09.003_bib88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2014.09.003_bib89","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/art.23198","article-title":"Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients","volume":"58","author":"Ribi","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib90","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A","article-title":"Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients","volume":"44","author":"Gayraud","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2014.09.003_bib91","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A\u00a0vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2014.09.003_bib92","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/ar4313","article-title":"Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)","volume":"15","author":"Thiel","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2014.09.003_bib93","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/rheumatology\/kes171","article-title":"Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients","volume":"51","author":"Jakiela","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2014.09.003_bib94","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.rdc.2014.09.003_bib95","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X14000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X14000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:13:42Z","timestamp":1760181222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X14000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0889857X14000921"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2014.09.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Landscape of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2014.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}